N/A N=37 Physical Therapy Intervention for Puerperal Mastitis
Mastitis
Primary: Breast and Nipple Pain — 0; 0; 1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=324 A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
Borderline Personality Disorder
Primary: Change From Baseline in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score — -7.27; -6.25 score on a scale — p=0.2430
N/A N=174 Expectations and Pain Control Advancement In surgeRy: The REPAIR Trial
Abuses Over-The-Counter/Prescription Medications · Pain, Postoperative · Opioid Use
Primary: Opioid Use at Approximately Two Weeks Post-op — 15; 22.5 MME
Phase 2 N=64 Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
B-Thalassemia
Primary: Percentage of Non-transfusion Dependent (NTD) Participants With a Hemoglobin Increase of ≥1.5 g/dL From Baseline for ≥14 Days — 0.0; 0.0; 0.0; 66.7 Percentage of…
N/A N=105 Investigational Test of a New Sleep Supplement
Sleep · Mood · Cognitive Performance
Primary: Sleep Diary- Sleep Latency — -2.1; -2.53 minutes — p=0.1543
N/A N=78 Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
Breast Cancer
Primary: Change From Baseline in Mean Weekly HFS Score Between Acupuncture and Usual Care Arms at the End of Week 10 — -5.3; -0.5 HFS score on a scale — p=0.0003
Phase 2 N=8 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
CAH - Congenital Adrenal Hyperplasia
Primary: Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average) — -69.48 percent change
Phase 2 N=29 Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Liposarcoma · Metastatic Liposarcoma
Primary: Number of Participants Who Were Progression Free — 12 Participants
Phase 4 N=14 Cannabidiol and CES1 Interactions in Healthy Subjects
Drug Interaction
Primary: Differences in the Geometric Mean Ratio (GMR) of the Peak Concentration (Cmax) Will be Compared Between the Two Exposure Conditions; i.e. Methylphenidate + CBD vs…
Phase 2 N=51 Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)
β-Thalassemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 50 Participants
Phase 3 N=1,515 A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 374; 437; 57 Participants
Phase 2 N=57 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
Lupus Nephritis
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 33; 18; 6; 3 Participants
N/A N=27 Tourniquets Increase Proximal Pressure
Blood Pressure
Primary: Systolic Blood Pressure During Application of the CAT Tourniquets — 129; 76 mmHg
N/A N=318 Implementing a Blended Care Model That Integrates Mental Healthcare and Primary Care Using Telemedicine and Care Management for Patients With Depression or Alcohol Use Disorder in Small Primary Care Clinics
Depressive Disorders · Alcohol Use Disorders · Post-traumatic Stress Disorder (PTSD)
Primary: Change in VR-12 Mental Component Summary Scores — 2.9; 5.1 score on a scale
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L